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Background: Dovitinib (TKI-258) is a receptor tyrosine kinase (RTK) inhibitor targeting fibroblast growth factor
receptor (FGFR) and further related RTKs. TKI-258 is under investigation as anticancer drug for the treatment of
various cancers including bladder cancer with aberrant RTK signaling. Here, we analyzed the responses of ten
human bladder cancer cell lines towards TKI-258 treatment in relation to the epithelial mesenchymal transition
(EMT) status of the cells.
Methods: Expression of epithelial marker E-cadherin as well as mesenchymal markers N-cadherin and vimentin was
determined by quantitative RT-PCR and Western-blot in RNA and protein extracts from the cultured cell lines. The
cell responses were analyzed upon addition of TKI-258 by viability/proliferation (XTT assay) and colony formation
assay for measurement of cell contact independent growth.
Results: The investigated bladder cancer cell lines turned out to display quite different EMT patterns as indicated
by the abundance of E-cadherin or N-cadherin and vimentin. Protein and mRNA levels of the respective components
strongly correlated. Based on E-cadherin and N-cadherin mRNA levels that were expressed approximately mutual
exclusively, an EMT-score was calculated for each cell line. A high EMT-score indicated mesenchymal-like cells and a
low EMT-score epithelial-like cells. Then, we determined the IC50 values for TKI-258 by dose response curves (0-12 μM
TKI-258) in XTT assays for each cell line. Also, we measured the clonogenic survival fraction after adding TKI-258 (1 μM)
by colony formation assay. We observed significant correlations between EMT-score and IC50 values (r = 0.637,
p = 0.0474) and between EMT-score and clonogenic survival fraction (r = 0.635, p = 0.0483) as analyzed by linear
regression analyses.
Conclusions: In sum, we demonstrated that the EMT status based on E-cadherin and N-cadherin mRNA levels may be
useful to predict responses towards TKI-258 treatment in bladder cancer.
Keywords: Receptor tyrosine kinase, Tyrosine kinase inhibition, Bladder cancer, Epithelial mesenchymal transition* Correspondence: joerg.haenze@med.uni-marburg.de
†Equal contributors
Department of Urology and Pediatric Urology, Philipps University of Marburg,
Baldingerstraße, 35043 Marburg, Germany
© 2013 Hänze et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hänze et al. BMC Cancer 2013, 13:589 Page 2 of 9
http://www.biomedcentral.com/1471-2407/13/589Background
Receptor tyrosine kinase (RTK) signaling is altered in
urothelial cancer. Namely, FGFR dependent signaling is
affected [1]. FGFR3 mutations causing ligand independent
dimerization and enhanced kinase activity with constitu-
tive FGFR3 activation are prevalent in low grade non
muscle invasive transitional cell carcinoma (TCC) whereas
overexpression of wild type FGFR3 is observed in muscle
invasive bladder cancer [2-4]. Also, aberrant expression of
FGFR1, FGFR2, and FGF2 ligand has been demonstrated
[5-7]. Further RTKs such as VEGFR and PDGFR are in-
volved in bladder cancer progression [8]. Therefore, drugs
for inhibition of RTKs are under investigation for the
treatment of bladder cancer. Among those, TKI-258 tar-
geting signaling of FGFR/PDGFR/VEGFR and further
related RTKs is investigated as a potential anti TCC com-
pound [9,10]. The affinity order for TKI-258 has been de-
termined for different RTKs being highest for FGFR1 and
FGFR3 followed by VEGFR1-3, PDGFRβ, FLT-3 and c-Kit
revealing the complexity of the drug [11]. The responsive-
ness towards RTK inhibitors is difficult to predict in blad-
der cancer [7,10]. Patients with non muscle invasive
bladder cancer have a good outcome and only a small
portion of these tumors progress to metastatic disease.
Muscle-invasive TCC is more prone to become metastatic
and oncological outcome is much poorer. An indicator of
metastatic potential is the EMT status [12]. EMT is associ-
ated with enhanced cell migration and metastasis reveal-
ing a more aggressive cancer type. Bladder cancer cells
can strongly differ in epithelial and mesenchymal charac-
teristics as revealed by different cadherin subtype expres-
sion patterns [13,14]. Cadherins are transmembrane cell
adhesion proteins that are important during development
and play a role in various diseases including cancer. E-
cadherin is expressed in epithelial cells. E-cadherin has
characteristics of a tumor suppressor that inhibits cell in-
vasion and loss of E-cadherin is important for induction of
EMT [15]. During EMT a cadherin switch occurs. E-
cadherin is replaced by N-cadherin a well established mes-
enchymal cell type marker in pathology [14]. P-cadherin is
a further cadherin subtype expressed in malignancies but
could not yet been assigned to an epithelial or mesenchy-
mal cell type in bladder cancer [14,16]. The mesenchymal
marker vimentin represents an intermediate filament that
replaces the epithelial cytokeratin filament [17]. The cad-
herin switch involves transcriptional regulation by epithe-
lial repressors (e.g. snail) for downregulation of E-cadherin
and mesenchymal activators (e.g. β-catenin) for upregula-
tion of N-cadherin [18].
Interestingly, unsupervised gene cluster analysis by glo-
bal gene expression profiling has demonstrated that non-
muscle invasive and muscle invasive TCC fall into two
distinct subgroups that identified EMT-related genes as
relevant [19-21]. The meaning of EMT status for drugresponses towards inhibition of epidermal growth factor
receptor has been reported in bladder cancer cells and re-
vealed a relevance of E-cadherin expression [22,23].
Here, we characterized ten human bladder cancer cell
lines with respect to expression of E-cadherin, N-cadherin
and vimentin. Furthermore, we analyzed the response of
these cells towards treatment with TKI-258 by prolife-
ration/viability assay and colony formation assay. We ob-
served that cells with epithelial characteristic had a
stronger therapeutically beneficial response to TKI-258
than cells with mesenchymal characteristics. Thus, ana-
lysis of the EMT status may help to predict TKI-258 re-




Human bladder cancer cell lines T24, HT1376, BFTC-
905, 5637, HU456, UMUC3, RT4, RT112, TCC-SUP,
MGHU4 were cultured in RPMI1640 medium supple-
mented with 10% fetal bovine serum, 1% stable glutam-
ine and 1% Penicillin/Streptomycin solutions (PAA
Laboratories, Pasching, Austria) at 37°C with 5% CO2 in
humidified air. Dovitinib (TKI-258) was kindly provided
by Novartis Pharma AG (Basel, Switzerland). RT4 and
RT112 cells are known to be wild type for FGFR3 and
T24 and UMUC3 have activating RAS mutations acting
downstream of RTKs [10].
RNA and protein extraction
RNA and protein extraction was performed with Trifast
(Peqlab, Erlangen, Germany) according to the manufac-
turer’s protocol.
Quantitative real time RT-PCR
1 μg RNA was used as template for cDNA synthesis after
digest of genomic DNA with RNase-free DNase (RevertAid
First Strand cDNA synthesis Kit, Fermentas Life Science,
St. Leon-Rot, Germany). Realtime RT-PCR was performed
with SYBR Green Fluorescein Mix (ABgene UK, Epsom,
UK). Cycling conditions were, 95°C for 15 min, followed by
45 cycles of 95°C for 15 s, 60°C for 15 s, 72°C for 30 s. Rela-
tive levels of mRNA are displayed as -ΔCt values with the
mean of β-actin and porphobilinogen deaminase (PBGD)
as reference mRNA (ΔCt = Cttarget mRNA – Ctreference mRNA).
The following primer sets (+, forward; −, reverse) were
employed: N-cadherin (+: CAA TCC TCC AGA GTT
TAC TGC CAT G, -: GAT TGG TTT GAC CAC GGT
GAC TAA C), E-cadherin (+: TGA AAA GAG AGT GGA
AGT GTC CGA G, -: GAT TAG GGC TGT GTA CGT
GCT GTT C), P-cadherin (+: GAC ACC TTC CGA GGG
AGT GTC TTA G, -: GGA TGG TCA GTG TGT ACT
CAG GGA C), Vimentin (+: GCA AAG CAG GAG TCC
ACT GAG TAC C, - TGT CAA GGG CCA TCT TAA
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ATG CG, -: CCC ACG CGA ATC ACT CTC AT),
FGFR3 (+: GAA AGA CGA TGC CAC TGA CAA GGA
C, -: TCC TTG AAG GTG AGC TGC TCC TC), β-
actin (+: TAT CCA GGC TGT GCT ATC CCT GTA C,
-: TTC ATG AGG TAG TCA GTC AGG TCC C) (Bio-
mers GmbH, Ulm, Germany). The EMT-score was de-
fined as (-Δct N-cadherin) – (-Δct E-cadherin).Western blot
After determination of protein concentration (Pierce
BCA Protein Assay, Thermo Scientific, Rockford, USA),
40 μg of each sample was subjected to sodium dodecyl
sulphate polyacrylamide gel electrophoresis (10% poly-
acrylamide) and transferred to polyvinylidene fluoride
membrane (Millipore, Bedford, USA) by electrophor-
esis. The membranes were blocked at room temperature
for 1.5 h. Primary antibodies for vimentin (dilution
1:2500), E-cadherin (dilution 1:5000), N-cadherin, (dilu-
tion 1:2000) (all of these polyclonal rabbit antibodies
(Abgent, San Diego, USA) and for β-actin (dilution
1:5000; monoclonal mouse Abcam, Cambridge, UK)
were added and incubated overnight at 4°C in tris-
buffered saline with 0.1% tween containing 5% dry milk.
Then, secondary horseradish peroxidase coupled anti-
rabbit or anti-mouse immunoglobulin (both dilution
1:2000; Thermo Scientific, Rockford, USA) was added
for band detection with enhanced chemiluminescent lu-
ciferase kit (Thermo Scientific, Rockford, USA) by an
image system (Fluorchem IS-8900, Alpha Innotech, San
Leandro, USA) allowing measurement of band intensity
for determination of relative protein abundance.Figure 1 Western-blot analysis of mesenchymal markers vimentin (VI
(ECDH) in comparison to cytoplasmic β-actin in various human bladd
strongly differ in the expression levels of VIM, NCDH and ECDH indicating mProliferation/viability assay
TACS XTT-Kit (Trevigen, Gaithersburg, USA) with a
long term protocol was used to assess the effects of
TKI-258 on cell viability, an assay that closely correlates
with proliferation. Cells were seeded into 96-well plates
with 150 μl medium and TKI-258 was added one day
later in a dose range as indicated (0.25 μM – 12 μM).
Medium and TKI-258 was replaced once after 2 d and
incubation continued for further 3 d. Then, XTT solu-
tion was added and the optical density was measured at
490 nm. The IC50 values were calculated by non-linear
regression analysis with the equation of a sigmoidal
dose response with variable slope (Graphpad Prism 5.0):
Y = 1/[1 + 10^(logIC50 ‐ X)(Hillslope)].Colony formation assay
This assay measures cell proliferation in a cell contact
independent way. Cells were plated in pre-tested appro-
priate densities yielding 100-500 cells per plate. The
plates were cultured for 8-12 days in the presence
(1 μM) or absence (0 μM) of TKI-258. Then, the colony
signals were densitometrically measured after crystal vio-
let staining. The clonogenic survival fraction was defined
as the ratio of signal intensity of untreated group versus
TKI-258 (1 μM) treated group.Results
We analyzed typical components indicating the epithelial
or mesenchymal cell status in ten human bladder cancer
cell lines. As epithelial marker we measured E-cadherin
and as mesenchymal markers N-cadherin and vimentin
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Figure 2 Quantification of mRNA encoding vimentin (VIM),
N-cadherin (NCDH) and E-cadherin (ECDH) by realtime RT-PCR
in human bladder cancer cell lines. Displayed are the -ΔCt values
(Ct, cycle of threshold) normalized to β-actin and PBGD mRNA
(mean, standard deviation, n≥ 3). The order of cell lines is the same
as in the Western-blot and allows direct comparison with Figure 1.
Linear regression analysis revealed strong correlation between mRNA
and protein levels of NCDH, ECDH and VIM, respectively (E-cadherin,
r = 0.831, p = 0.0029; N-cadherin, r = 0.794, p = 0.0061; vimentin,
r = 0.858, p = 0.0015).
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vimentin was predominantly expressed in those cells that
were N-cadherin positive. Next, we quantified the mRNA
levels of these components (Figure 2). We revealed strong
correlation between mRNA and protein levels suggesting
major regulation of these components at the mRNA level.
In addition, we analyzed P-cadherin and FGFR3 (Figure 3).
The role of P-cadherin has been ambiguously described in
EMT status. FGFR3 was analyzed since FGFR3 was dem-
onstrated to correlate with epithelial markers. Interest-
ingly, we revealed a correlation between P-cadherin and
E-cadherin-mRNA levels (r = 0.919, p < 0.0001) and could
confirm the correlation between FGFR3 and E-cadherin-
mRNA (r = 0.813, p < 0.0001).
Based on the well established and related endpoint
markers of EMT status, E-cadherin and N-cadherin, we
calculated an EMT-score for each cell line by subtraction
of -ΔCt N-cadherin and -ΔCt E-cadherin, respectively
(Figure 4). In this term, high values reflect a mesenchymal
status and low values an epithelial status. Based on this
EMT-score, we analyzed the cell responses towards TKI-
258 treatment. Employing a proliferation/viability assay,
we measured the inhibitory concentration of TKI-258
yielding 50% viable cells (IC50 value) by establishing dose
response curves for each cell line (Figure 5A, B). Fur-
thermore, we performed colony formation assay for the
measurement of cell contact independent growth. We de-
termined the clonogenic survival fraction by calculating
the ratio of cells treated with TKI-258 (1 μM) compared
to untreated control (0 μM) (Figure 6A, B). These data
were analyzed by linear regression analyses between the
EMT-score (data from Figure 4) and the IC50 value (data
from Figure 5B) and between the EMT-score and the clo-
nogenic survival fraction (data from Figure 6B). We ob-
served significant correlations between EMT-score and
IC50 values (Figure 7A) and between EMT-score and clo-
nogenic survival fractions (Figure 7B).
In conclusion, the EMT status as determined by E-
cadherin and N-cadherin mRNA levels demonstrated
significant correlation with cellular TKI-258 responses
as studied by different experimental approaches in blad-





































Figure 4 Calculation of an EMT-score for each bladder cancer
cell line by subtraction of –Δct [NCDH] - –Δct [ECDH] (data from
Figure 2). This score allows quantitative evaluation of mesenchymal





































































Figure 3 Quantification of P-cadherin (PCDH) and fibroblast
growth factor receptor 3 (FGFR3) mRNAs by realtime RT-PCR in
human bladder cancer cell lines. Displayed are the -ΔCt values
(Ct, cycle of threshold) normalized to β-actin mRNA and PBGD
mRNA (mean, standard deviation, n ≥ 3).
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The EMT status reflects features of cancer cells that favor
cell migration and invasion, characteristics that are linked
to metastasis. Epithelial-like cells are crucially character-
ized by E-cadherin and mesenchymal-like cells by N-
cadherin expression. In cancer, the EMT status reflects the
issue of complex cell signaling mechanisms including RTK
pathways [24]. Aberrant signaling of RTKs has been de-
scribed in bladder cancer [25]. Therefore, TKIs are studied
for therapy of bladder cancer however, the therapeutic re-
sponses vary and are difficult to predict.
Here, we investigated the EMTstatus in bladder cancer cell
lines and tested whether the EMT status is associated with
therapeutic responses towards TKI-258. Most importantly,we demonstrated: 1) E-cadherin and N-cadherin pro-
tein levels were expressed complementary and corre-
lated with their respective mRNA levels. 2) N-cadherin
and E-cadherin mRNA levels served for calculation of
an EMT-score indicating the EMT status. High values
reflected a relative mesenchymal cell type and low values
an epithelial-like cell type. 3) Analysis of the EMT-score
and cell responses towards TKI-258 treatment revealed
correlations that indicated epithelial-like cells as more
therapeutically responsive than mesenchymal-like cells.
Beside the well defined role of E-cadherin and N-
cadherin in EMT, we also included P-cadherin in our
studies. We observed striking correlation of P-cadherin
and E-cadherin mRNA levels supporting a possible associ-
ation of P-cadherin with epithelial characteristics. This
finding is in line with studies where P-cadherin was ob-
served to be enhanced in low grade non muscle invasive
bladder cancer indicating epithelial differentiation [16,26].
Other studies revealed correlation of P-cadherin levels
with increasing tumor and grading stage indicating a mes-
enchymal characteristic [14,27,28]. In contrast, the role of
N-cadherin and E-cadherin in EMT is clearly defined.
Therefore, calculation of an EMT-score based on these
cadherin subtypes appeared reasonably and revealed corre-
lations with TKI258 responses in all cell assays performed.
Noteworthy, RTK signaling is related to the expres-
sion of epithelial and mesenchymal markers. In particu-
lar, FGFR3 mRNA correlated with E-cadherin mRNA
[7] as confirmed in the cell lines in our study. Further-
more, FGFR1 mRNA expression (not investigated in
our study) correlated with the mesenchymal marker N-
cadherin [7]. Thus, the analysis of the EMT may be an
alternate clue to predict responses towards inhibition of
RTK signaling in cancer cells without the need to
AB





































































































































































Figure 5 Calculation of IC50 values for TKI-258 treatment. A) Proliferation/viability XTT assay in human bladder cancer cell lines. The IC50
values were determined by curve fitting with non-linear regression analysis (sigmoidal dose response). B) The IC50 values for each cell line are
summarized.


























































TKI-258         UMUC3            HU456           HT1376             T24            TCCSUP
0 µM
1 µM
TKI-258           5637              MGHU4          RT112           BFTC905          RT4
0 µM
1 µM
Figure 6 Calculation of the clonogenic survival fraction after TKI-258 treatment. A) Colony formation assay of control cells TKI-258 [0 μM]
and cells treated with TKI-258 [1 μM]. Displayed are the plates after staining with crystal violet. B) The ratio of signal intensity of the plates treated
with TKI-258 [1 μM] versus control [0 μM] is displayed indicating the clonogenic survival fraction as a quantitative parameter of treatment
efficiency with TKI-258.
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components by molecular diagnostics. Noteworthy, pre-
diction of cellular responses towards TKI-258 solely
based on mutation studies of FGFR have failed and the
identification of superior biomarkers is desirable [10].
The analysis of EMT parameters as performed in ourstudy in human cancer cell lines would be also applic-
able for tumor tissue samples.
Restrictively, it has to be addressed that TKI-258 targets
several RTKs namely those of the ligands VEGF, PDGF and
FGF that represent growth and angiogenic factors [1,29].
Thus, in vivo effects of TKI-258 are certainly more complex
AB













































Figure 7 Linear correlation analyses of the EMT-score with
TKI-258 responses. A) Correlation of EMT-score and IC50 values
(r = 0.637, p = 0.0474). B) Correlation of EMT-score and clonogenic
survival fraction (r = 0.635, p = 0.0483). The dotted lines represent
the 95% confidence band of the best fit, respectively.
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http://www.biomedcentral.com/1471-2407/13/589and comprise effects on tumor angiogenesis. Moreover, ef-
fects of TKI-258 have not only been attributed to inhibition
of RTKs. Namely, topoisomerase II has been demonstrated
as target of TKI-258 causing cytotoxic DNA double strand
breaks [30].Conclusions
Aberrant cellular processes that contribute to bladder
tumorigenesis comprise altered signaling of RTKs. Thus,
tyrosine kinase inhibitors such as TKI-258 are under in-
vestigation for the treatment of bladder cancer. Here we
demonstrated that the EMT status determined by E-
cadherin and N-cadherin expression levels is associated
with responses towards TKI-258 treatment. In particular,
TKI-258 was more effective in epithelial-like than in
mesenchymal-like bladder cancer cells. Therefore, deter-
mination of the EMT status may be exploited as putative
predictor for treatment responses of TKI-258 in bladder
cancer.Competing interests
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